Europe Viscosupplementation Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Europe Viscosupplementation Market Size

• The Europe Viscosupplementation market size was valued at USD 517.39 million in 2024 and is expected to reach USD 957.66 million by 2032, at a CAGR of 8.00% during the forecast period
• The market growth is largely driven by the increasing prevalence of osteoarthritis, particularly among the aging population, and the growing preference for minimally invasive treatment options for joint pain management
• Furthermore, rising awareness about viscosupplementation as a safer alternative to surgical interventions and improvements in hyaluronic acid formulations are enhancing treatment efficacy. These converging factors are contributing to a higher adoption of viscosupplementation procedures, thereby supporting steady market expansion across the region

Europe Viscosupplementation Market Analysis

• Viscosupplementation, involving the injection of hyaluronic acid into synovial joints, is increasingly recognized as an effective treatment option for osteoarthritis-related joint pain, particularly in the knee, due to its ability to restore joint lubrication and improve mobility without the need for surgery
• The rising demand for viscosupplementation across Europe is primarily driven by the growing geriatric population, increasing prevalence of osteoarthritis, and a strong preference for non-invasive, outpatient-based pain management therapies
• Germany dominated the viscosupplementation market with the largest revenue share of 42% in 2024, supported by its advanced healthcare infrastructure, significant aging population, and early adoption of non-surgical orthopedic treatments
• Turkey is expected to be the fastest growing country in the viscosupplementation market during the forecast period due to its expanding healthcare sector, increasing access to advanced therapies, and rising public awareness about minimally invasive osteoarthritis treatments
• The single-injection segment dominated the viscosupplementation market with a market share of 46.3% in 2024, owing to its convenience, reduced treatment burden on patients, and comparable efficacy to multi-injection regimens

Report Scope and Europe Viscosupplementation Market Segmentation      

Europe Viscosupplementation Market Trends

“Enhanced Convenience Through AI and Voice Integration”

• A significant and accelerating trend in the Europe viscosupplementation market is the shift toward single-injection regimens and the development of more biocompatible, cross-linked hyaluronic acid (HA) formulations that offer longer-lasting joint lubrication and reduced treatment frequency
  • For instance, products such as Synvisc-One and Durolane have gained widespread adoption in markets such as Germany and France due to their ability to deliver sustained relief from knee osteoarthritis symptoms with just one injection
• Single-injection therapies are increasingly preferred by both physicians and patients as they reduce clinic visits, lower the risk of infection, and improve overall treatment adherence. Moreover, new-generation HA products with enhanced viscoelastic properties are delivering better outcomes with minimal adverse effects
• Advances in formulation science are also enabling viscosupplementation products to target multiple joints, not just the knee, broadening their clinical utility. In addition, pharmaceutical companies are exploring biosynthetic and animal-free HA sources to enhance product safety and address ethical concerns, aligning with growing consumer preference for clean and biocompatible therapies
• The trend toward convenient, patient-friendly therapies is prompting companies such as Fidia Farmaceutici and Anika Therapeutics to focus on R&D that delivers improved efficacy with fewer interventions
• Demand for single-dose, longer-acting HA injections is growing rapidly across both public and private healthcare settings in Europe, driven by cost-effectiveness, clinical efficiency, and better patient satisfaction

Europe Viscosupplementation Market Dynamics

Driver

“Rising Osteoarthritis Burden and Preference for Non-Surgical Pain Management”

• The increasing incidence of osteoarthritis across Europe’s aging population, coupled with a growing preference for non-surgical and outpatient treatment options, is a major driver fueling the demand for viscosupplementation therapies
  • For instance, health authorities in countries such as Germany and the UK are encouraging earlier intervention for knee osteoarthritis with injectable therapies to delay the need for joint replacement surgeries. Such initiatives are fostering greater adoption of viscosupplementation in primary care settings
• Patients and healthcare providers are increasingly favoring HA injections over long-term NSAID use due to their reduced systemic side effects and potential to improve joint function more sustainably
• The availability of reimbursed viscosupplementation therapies in many European countries, along with advancements in injection techniques and shorter recovery times, is further boosting market growth
• The convenience, safety, and effectiveness of viscosupplementation, particularly in elderly patients or those unfit for surgery, make it an attractive solution for managing chronic joint pain across both urban and rural regions of Europe

Restraint/Challenge

“Regulatory Constraints and Variability in Reimbursement Policies”

• Regulatory complexities and inconsistent reimbursement frameworks across different European countries present a key challenge to the expansion of viscosupplementation therapies
  • For instance, while Germany and France provide broader reimbursement coverage for HA injections, countries such as Spain and the UK have more restrictive reimbursement policies, limiting access for certain patient groups
• In addition, the classification of viscosupplements whether as medical devices or drugs varies by country, complicating approval pathways and market entry strategies for manufacturers
• Some clinical bodies in Europe have expressed uncertainty over the long-term cost-effectiveness of viscosupplementation, leading to inconsistent clinical guidelines and treatment adoption patterns
• Overcoming these challenges will require harmonization of reimbursement criteria, generation of robust clinical evidence supporting long-term efficacy, and active engagement with policymakers to broaden treatment access across diverse healthcare systems in Europe

Europe Viscosupplementation Market Scope

The market is segmented on the basis of source, molecular weight, injection type, age group, end user, and distribution channel.

• By Source

On the basis of source, the Europe viscosupplementation market is segmented into non-animal origin and animal origin. The non-animal origin segment dominated the market with the largest market revenue share in 2024, driven by its lower immunogenic risk, absence of animal-derived contaminants, and increased patient preference for ethically sourced products. Non-animal HA is widely accepted in Europe due to strict regulatory compliance and growing demand for safer, synthetic alternatives. Manufacturers continue to invest in fermentation-based HA production technologies to meet the region’s rising demand.

The animal origin segment, is expected to witness fastest growth during forecast period due to cost-effectiveness, widespread clinical familiarity, and continued use in private healthcare settings where reimbursement constraints are less restrictive. In addition, some practitioners prefer animal-derived HA for its natural viscoelastic properties and historical efficacy.

• By Molecular Weight

On the basis of molecular weight, the Europe viscosupplementation market is segmented into low molecular weight, intermediate molecular weight, and high molecular weight. The intermediate molecular weight segment held the largest market revenue share in 2024, as it offers an optimal balance between viscosity, durability, and joint lubrication, making it suitable for treating mild to moderate osteoarthritis. It is frequently used in both single and multi-injection regimens and is favored in countries such as France and Spain for its clinical reliability.

The high molecular weight segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by its superior viscoelastic properties, longer residence time in the joint, and ability to provide extended relief with fewer injections. This segment is gaining traction in Germany and the UK where patient outcomes and long-term efficacy are top priorities.

• By Injection

On the basis of injection type, the Europe viscosupplementation market is segmented into single injection, three injection, and five injection. The single injection segment dominated the market with the largest market revenue share of 46.3% in 2024, driven by its convenience, reduced treatment burden, and improved patient adherence. The appeal of one-time procedures is particularly strong in outpatient and ambulatory care settings, making it a popular choice among elderly and working-age populations.

The three injection segment is projected to maintain fastest growth during forecast period, especially in countries where traditional treatment cycles are still preferred by clinicians.

• By Age Group

On the basis of age group, the Europe viscosupplementation market is segmented into geriatric and adult. The geriatric segment dominated the market with the largest market revenue share in 2024, driven by the high prevalence of osteoarthritis among aging individuals across Europe, especially in Italy, Germany, and the UK. As life expectancy rises and the senior population grows, demand for non-surgical joint pain relief options such as viscosupplementation continues to increase.

The adult segment is projected to maintain fastest growth during forecast period, supported by early-onset arthritis, post-injury degeneration, and increased awareness of preventive joint care in individuals under 60.

• By End User

On the basis of end user, the Europe viscosupplementation market is segmented into hospitals, orthopaedic clinics, ambulatory care centers, and others. The hospital segment accounted for the largest market revenue share in 2024, due to their role as primary providers of advanced osteoarthritis treatments and their access to reimbursed viscosupplementation procedures. Hospitals remain the leading choice for patients with severe or complex cases requiring multidisciplinary care.

The orthopaedic clinics segment is expected to witness the fastest growth rate from 2025 to 2032, driven by increasing patient preference for specialized, outpatient treatment environments and the expansion of standalone musculoskeletal centers across Europe. Clinics offer faster service, focused expertise, and cost-efficiency, contributing to their growing adoption.

• By Distribution Channel

On the basis of distribution channel, the Europe viscosupplementation market is segmented into direct tender and retail sales. The direct tender segment dominated the market with the largest market revenue share in 2024, as public and private hospitals across countries such as France, Germany, and the Netherlands procure viscosupplementation products through centralized tender systems. These bulk purchases ensure consistent supply and cost savings, particularly in the public healthcare sector.

The retail sales segment is projected to maintain fastest growth during forecast period, fueled by rising demand for over-the-counter and private-label viscosupplementation solutions in pharmacies and online platforms. Patients paying out-of-pocket or seeking faster access to care increasingly prefer retail channels, especially in markets with limited reimbursement.

Europe Viscosupplementation Market Regional Analysis

• Germany dominated the Europe viscosupplementation market with the largest revenue share of 42% in 2024, supported by its advanced healthcare infrastructure, significant aging population, and early adoption of non-surgical orthopedic treatments
• Patients and healthcare providers in Germany increasingly prefer viscosupplementation due to its ability to delay surgical interventions and offer sustained relief with minimal side effects
• This growing adoption is further supported by favorable reimbursement policies, rising geriatric population, and the presence of leading manufacturers, establishing viscosupplementation as a widely accepted treatment option in both public and private healthcare settings

Germany Viscosupplementation Market Insight

The Germany viscosupplementation market captured the largest revenue share in Europe in 2024, supported by a strong healthcare infrastructure, high osteoarthritis incidence, and early adoption of advanced therapeutic solutions. German clinics and hospitals are increasingly incorporating viscosupplementation into standard OA treatment protocols, particularly among elderly patients. The country’s robust reimbursement framework, combined with ongoing clinical research and presence of key players, continues to drive market expansion and innovation in hyaluronic acid formulations.

Turkey Viscosupplementation Market Insight

The Turkey viscosupplementation market is projected to grow at the fastest CAGR in Europe during the forecast period, driven by expanding healthcare infrastructure, a rising osteoarthritis burden, and strong patient demand for non-surgical treatment options. Government investments in hospital development and the growth of medical tourism are increasing access to viscosupplementation therapies. In addition, the affordability of HA injections and growing physician awareness are helping Turkey emerge as a key growth engine in the European market.

France Viscosupplementation Market Insight

The France viscosupplementation market is expected to grow at a substantial CAGR throughout the forecast period, fueled by a proactive approach to managing osteoarthritis through minimally invasive solutions. French healthcare providers are increasingly relying on viscosupplementation to delay the need for joint replacement surgeries. Supportive insurance coverage and high patient awareness regarding non-surgical options are accelerating adoption across both public and private healthcare systems.

Italy Viscosupplementation Market Insight

The Italy viscosupplementation market is gaining momentum, supported by its aging demographic and rising focus on joint preservation therapies. Italian healthcare providers are adopting viscosupplementation as a standard option in orthopedic practices, especially in urban areas. Government-backed healthcare services and the availability of local and international product brands are making viscosupplementation more accessible to patients.

U.K. Viscosupplementation Market Insight

The U.K. viscosupplementation market is anticipated to expand steadily, driven by increasing demand for outpatient orthopedic care and growing awareness of early intervention in osteoarthritis treatment. Although reimbursement policies remain somewhat conservative, the rise in private healthcare usage and the growing elderly population are contributing to increased adoption. The country’s emphasis on patient-centered care and mobility preservation is expected to support further market penetration.

Europe Viscosupplementation Market Share

The Europe Viscosupplementation industry is primarily led by well-established companies, including:

• Fidia Farmaceutici S.p.A. (Italy)
• Anika Therapeutics, Inc. (U.S.)
• Seikagaku Corporation (Japan)
• Bioventus LLC (U.S.)
• TRB Chemedica AG (Switzerland)
• Sanofi (France)
• Smith & Nephew (U.K.)
• Zimmer Biomet Holdings, Inc. (U.S.)
• LG Chem, Ltd. (South Korea)
• Bioiberica S.A.U. (Spain)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Ferring Pharmaceuticals (Switzerland)
• Hyaltech Ltd. (U.K.)
• Pharmascience Inc. (Canada)
• Virchow Biotech Pvt Ltd. (India)
• IBSA Institut Biochimique SA (Switzerland)
• Chugai Pharmaceutical Co., Ltd. (Japan)
• Viatris Inc. (U.S.)
• Korea Pharma Co., Ltd. (South Korea)

What are the Recent Developments in Europe Viscosupplementation Market?

• In March 2024, Fidia Farmaceutici S.p.A., a leading Italy-based biopharmaceutical company, announced the expansion of its hyaluronic acid (HA) production facility in Abano Terme to meet rising European demand for viscosupplementation therapies. The upgraded site is expected to increase output of single-injection and cross-linked HA formulations, reinforcing Fidia's leadership in the OA treatment segment and improving supply chain responsiveness across major European markets
• In February 2024, Anika Therapeutics, Inc. partnered with select orthopedic clinics in Germany and France to roll out a clinical support initiative promoting early-stage viscosupplementation for knee osteoarthritis. The program includes physician training and patient education to drive awareness and adoption of Anika’s HA-based injections, aligning with broader goals to reduce reliance on NSAIDs and delay surgical interventions
• In January 2024, TRB Chemedica AG introduced a new generation of high molecular weight hyaluronic acid under the brand name ViscoFlow Pro across Switzerland and the Benelux region. The product launch highlights growing interest in premium viscosupplementation therapies that offer prolonged efficacy and improved patient outcomes with fewer injections. This move supports TRB’s strategy to strengthen its European orthopedic portfolio
• In November 2023, Bioventus Inc. completed a multi-country post-market clinical evaluation of its Durolane single-injection HA therapy across Spain, the UK, and Italy. Results demonstrated high patient satisfaction and clinically significant improvements in pain and mobility, bolstering clinical evidence supporting broader reimbursement discussions and real-world use in European outpatient settings
• In October 2023, Seikagaku Corporation, through its European distribution partner, expanded access to its SUPARTZ FX viscosupplementation solution in Poland and Eastern Europe. The expansion supports the company’s strategic aim to reach underpenetrated markets with growing OA burdens and limited surgical alternatives, contributing to regional equity in OA care through minimally invasive injectable solutions

SKU-68855